Adalvo will proceed with the DCP submission for Tofacitinib film-coated tablets this March, ensuring readiness for a Day-1 launch following the expiry of regulatory exclusivity.
Tofacitinib, developed based on the reference brand Xeljanz, is a Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and juvenile idiopathic arthritis. By targeting key inflammatory pathways, it has demonstrated significant efficacy in alleviating symptoms.
Its oral administration offers ease of use functionality, integrating seamlessly into patients’ daily routines and promoting improved adherence to therapy.
With global sales of $3.3 billion in 2023, according to IQVIA, Tofacitinib has established itself as an important treatment in managing inflammatory conditions.
By acting swiftly as exclusivity expires, Adalvo strengthens its position as a leader in delivering high-quality, differentiated and accessible therapies to the market.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!